|
|
|
Scholar Rock Holding Corp (NASDAQ: SRRK) |
|
Scholar Rock Holding Corp
SRRK's Fundamental analysis
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
|
Scholar Rock Holding's sales fell
in the first quarter of 2025 from the same quarter a year ago.
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 12.78 %
Scholar Rock Holding net loss increased from $-57 millions, to $-75 millions in first quarter of 2025,
• More on SRRK's Growth
|
|
Scholar Rock Holding
realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 91.13 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.4.
• More on SRRK's Valuation
|
|
|
|
|
Scholar Rock Holding
realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 91.13 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.4.
Scholar Rock Holding Price to Book Ratio is at 13.41 lower than Industry Avg. of 2011.58. and higher than S&P 500 Avg. of 0.01
• More on SRRK's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
